0000899243-20-001167.txt : 20200114
0000899243-20-001167.hdr.sgml : 20200114
20200114164055
ACCESSION NUMBER: 0000899243-20-001167
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200113
FILED AS OF DATE: 20200114
DATE AS OF CHANGE: 20200114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PRESTRELSKI STEVEN
CENTRAL INDEX KEY: 0001744027
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38536
FILM NUMBER: 20526400
MAIL ADDRESS:
STREET 1: C/O XERIS PHARMACEUTICALS
STREET 2: 180 N. LASALLE STREET, SUITE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001346302
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203352427
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: SUITE 1600
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-13
0
0001346302
XERIS PHARMACEUTICALS INC
XERS
0001744027
PRESTRELSKI STEVEN
C/O XERIS PHARMACEUTICALS, INC.
180 N. LASALLE STREET, SUITE 1600
CHICAGO
IL
60601
0
1
0
0
Chief Scientific Officer
Common Stock
2020-01-13
4
S
0
10000
5.4992
D
421824
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
$5.4992 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.31 to $5.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/Beth Hecht, as Attorney-in-Fact
2020-01-14